A specific interleukin-1 (IL-1) receptor antagonist (IL-lra) was used to examine the roles of IL-1 in an experimental model designed to analyze the reactivation phase of erosive arthritis, induced in rats with peptidoglycan-polysaccharide polymers (PG-APS) isolated from cell walls of group A streptococci. Monoarticular arthritis was initiated by injection of a small dose of PG-APS into an ankle joint, and reactivation was induced by intravenous injection of PG-APS 20 days later. Human recombinant IL-lra given at a dose of 2 to 3 mg/kg at the time of reactivation of arthritis and at 6-h intervals inhibits the increase in joint swelling by at least 60%. Joint swelling is suppressed 30 to 50% when the initial treatment with IL-lra is delayed until 6 h after reactivation. IL-lra is not effective when the initial injection is delayed 12 or 24 h. With an injection schedule of IL-lra given at the time of reactivation and every 6 h, treatment can be stopped at 24 h and the suppression of swelling is no different from that in rats for which injections are continued for 4 days. The results indicate that IL-1 has a prominent, although not exclusive, role in initiating inflammation in this model and is involved in the amplifying processes in progressive inflammation and chronic erosive disease. An antiinflammatory function of IL-1 is also indicated from data showing that IL-Ira treatment limited to 6 h or less after the induction of reactivation enhances joint swelling, whereas intravenous injection of human recombinant IL-113 24 h before reactivation suppresses the reactivation of arthritis.
A single systemic injection of rats with an aqueous suspension of purified peptidoglycan-polysaccharide polymers (PG-APS) isolated from cell walls of group A streptococci can induce inflammation of peripheral joints characterized by repeated episodes of waxing and waning and progressing over a period of several months to joint destruction (9, 19) . The most striking feature of this disease is the spontaneous recurrence of inflammation which, along with histological and radiological findings, resembles human rheumatoid arthritis (7, 10) . Although most of the peripheral joints become involved following systemic injection of PG-APS, it is difficult to analyze the molecular events regulating recurrence, because recurrence is random and unpredictable for a given joint. Therefore, we have modified this model to synchronize reactivation. Monoarticular arthritis is induced by intraarticular (i.a.) injection of an ankle joint with a small dose of PG-APS, producing a synovitis which reaches a peak in 24 h and then recedes over the next several days (14) . Reactivation is induced by intravenous (i.v.) injection of a normally subarthropathic dose of PG-APS (13) or lipopolysaccharide (23) 1 to 8 weeks later, producing a more prolonged, severe, chronic inflammation confined to the joint previously injured by PG-APS.
The involvement of interleukin-1 (IL-1) in inflammatory arthritis is suggested by reports of increased levels of IL-1 in joint effusions from rheumatoid arthritis patients (29) and a correlation of plasma levels with disease activity (11) . i.a. injection of rabbits (18) , mice (27) , and rats (22) demonstrates the capacity of IL-1 to initiate inflammation which, however, is not sustained. We have reported that IL-la or IL-13 can reactivate arthritis in a joint injured previously by * Corresponding author.
PG-APS and that repeated injections can lead to marginal cartilage erosion (22) .
Recent reports have described an IL-1 receptor antagonist (IL-lra) produced by human monocytes grown on adherent immune complexes (1, 2) . A cDNA encoding this protein has been isolated and expressed in Escherichia coli (12) . The cDNA for an IL-1 inhibitor has subsequently been cloned from U937 cells (5) , and this predicted protein is identical in sequence to that reported by Hannum et al. (15) . The biological activity of the recombinant protein has been demonstrated in vitro by inhibition of IL-1 stimulation of prostaglandin E2 production by human foreskin fibroblast cells (12, 15) , synovial cells, and chondrocytes (3) and by inhibition of collagenase secretion by synovial cells stimulated by IL-1 (3). IL-lra can block IL-1 action in vivo (17) , prevent septic shock and death induced in rabbits by endotoxin (17) or E. coli (28) , and reduce acute pulmonary inflammation induced by intratracheally administered endotoxin (26) . We report here the use of this inhibitor of IL-1 activity in an examination of the role of IL-1 in the course of a progressive, chronic inflammatory response, namely, the bacterial cell wall model of reactivation of inflammatory arthritis. Two assessments, joint swelling and histological evidence of cartilage and bone erosion, were used.
MATERIALS AND METHODS
Preparation of PG-APS. Streptococcus pyogenes type 3 strain D-58 was grown in Todd-Hewitt broth (BBL, Cockeysville, Md.) to the early stationary phase. Cells were harvested, washed by centrifugation, and broken in a DynoMill (Glen Mills, Inc., Maywood, N.J.). The cell wall fragments were collected by differential centrifugation, extracted three times with 2% sodium dodecyl sulfate, washed extensively with pyrogen-free water, and lyophilized. The cell wall particles, consisting of large PG-APS polymers, were further fragmented by sonication and separated by centrifugation into a fraction referred to as 100p PG-APS, which was soluble at 10,000 x g but sedimented at 100,000 x g. PG-APS was quantitated on the basis of its rhamnose content, which was approximately 30%. Aseptic techniques were used throughout. The details of the methods used to monitor purification have been recently described (24) .
Induction of recurrence of arthritis. Female Lewis rats (Charles River, Triangle Park, N.C.) weighing about 175 g were injected i.a. under ether anesthesia above the calcaneus through the Achilles tendon into the tibiotalar (ankle) joint on day 0 with 2.0 ,Ig of rhamnose equivalents (approximately 6.0 ,ug [dry weight]) of 100p PG-APS suspended in 10 LI of pyrogen-free saline as described previously (5, 6 Corp ., New York, N.Y.). The precision of this method has been described previously (22, 24) . To reduce bias, we coded all groups, and the person holding the rat selected the animal from cages at random and presented it so that no identification was visible to the person making the measurement. Joints were measured before i.a. and i.v. injections and daily thereafter. The data are expressed in Fig. 1 as joint diameter to illustrate the course of the disease and in subsequent figures as the change in the joint diameter from the pre-i.v. measurement, providing a control for individual animal variations.
For the histological study ofjoint sections, rats were killed with CO2 and ankle joints were removed, skinned, fixed in Formalin, decalcified, embedded in paraffin, sectioned sagitally, and stained with hematoxylin and eosin. To limit sampling variability, we marked the middle of each tissue from the center of the heel with black ink before embedding was done, and rough cuts were made to this mark before sections were removed for staining. Sagital sections through or near the center of each ankle joint were graded 0 to 4+ for the severity of synovitis in the involved joint spaces, the degree of bursitis surrounding the Achilles tendon, and the amount of cartilage and bone erosion in the ankle joint. Observer bias was reduced by blindly reevaluating each coded section after the initial histological assessment.
Statistical analysis. The level of significance of differences between groups was calculated by Student's two-tailed t test.
IL-lra. Human recombinant IL-lra was prepared from reduced when the interval between injections was 12 h, when an initial injection was given at the time of induction of the recurrence, and when a dose of IL-lra of 8 mg/kg was used ( Fig. 1 ). When the intervals were increased to 24 h, for a total of four injections over 96 h, reactivation was not suppressed, even with a dose of 32 mg/kg per injection (data not shown). These results indicate that IL-1 plays a critical role in the early stages of recurrence of joint swelling and that, when IL-1 activities are unchecked for an interval of more than 12 h, it is no longer possible to intervene by blocking only IL-1 binding to its receptor.
Consistent with the assumption that IL-lra works through blocking of the IL-1 receptor is the observation that the suppression of the increase in ankle joint swelling was dependent on the dose of IL-lra, which was effective over a range of 0.3 to 8.0 mg/kg, employing the schedule described in the legend to Fig. 2 . The maximum suppression of ankle joint swelling was 55% and the 50% effective dose was 0.5 mg/kg per injection with this schedule.
To further establish at what stages of the evolving process IL-1 plays a prominent role, i.e., initiating and/or maintaining inflammation, we next determined how long the initial IL-lra treatment can be delayed or how long it must continue to be given. Definite but reduced suppression (average inhibition from days 1 to 11 after reactivation, 38%) was achieved when the initial injection of IL-lra was delayed until 6 h after the reactivation stimulus, at which time the increase in joint swelling was already evident (Fig. 3A, group  II) . When the initial injection of IL-lra was delayed until 12 or 24 h after the reactivation stimulus, further recurrence of inflammation was not suppressed (data not shown). Thus, although IL-1 plays an important role in early joint swelling, by 12 h other pathways have become involved and blocking only IL-1 is not sufficient.
To try to answer the question of the requirement for IL-1 in sustaining more prolonged inflammation, we determined the effect of stopping IL-lra treatment at 24 h. When IL-lra was begun at the time of PG-APS reactivation and continued every 6 h at a dose of 2 mg/kg, treatment could be stopped at 24 h and the subsequent course of joint swelling was no different from that in rats for which injections were continued every 6 h for 4 days (Fig. 4) . Thus, continued blocking of IL-1 beyond 24 to 36 h is not required for continued suppression of soft tissue swelling.
Anti-inflammatory role of IL-1. We were surprised to find that when IL-lra administration was limited to a more brief period, there was a trend toward enhanced rather than depressed inflammation. When IL-lra treatment was stopped at 6 h after reactivation, joint swelling became more severe than in the vehicle control group (Fig. 3A) . This difference from the control group was consistent and statistically significant at day 4. The severity of joint swelling in the group in which IL-lra was stopped at 6 h after reactivation was significantly greater on all days from 1 to 11 than it was in the group in which IL-lra injections began at 6 h (Fig.   3A) .
In a separate experiment, in which injections of IL-lra were given at the time of reactivation and only at 2 h later ( Fig. 3B) , joint swelling was again consistently more severe than it was in the vehicle control group (significant at day 5) and the severity was significantly greater from days 2 to 11 than it was in the group given more prolonged IL-lra .c. every 6 h for 24 h, and then PBS every 6 h for 84 h;@*, group II, IL-ira, on the same schedule as that of group I, except that IL-ira was continued for 84 h; 0, group III, PBS on the same schedule as that of group I. *, P < 0.01; +, P < 0.05 (both compared with PBS control).
treatment (Fig. 3B) . In another experiment, in which IL-lra was injected only once, at the time of reactivation, joint swelling was not different from that in the control group at any time in the succeeding 16 days (data not shown). These results suggested that since brief, early suppression of IL-1 activity by IL-ira actually increased joint inflammation, endogenous IL-i might play a role in down-regulating some facets of the very early inflammatory response. Both pro-and anti-inflammatory consequences were detected when IL-1,B was injected i.v. 24 h before reactivation by i.v. injection of PG-APS (Fig. 5) . Injection of 1.0(bg of human recombinant IL-g. i.v. induced renewed swelling, which was detectable by 1 h and reached a peak at 6 h, in the joint previously injected i.a. with PG-APS. However, the recurrence of joint inflammation subsequently induced by i.v. injection of PG-APS was significantly lower than that in the control group at 3 and 6 days after the induction of a recurrence (Fig. 5) .
EfIfect of IL-ra on histological changes in joint tissue.
Destruction of cartilage and bone is a feature of rheumatoid arthritis and of joint disease induced by PG-APS in rats. In vitro, IL-ira can prevent the IL-i-induced resorption of cultured bone (20) . Therefore, we assessed the influence of IL-ira on the cartilage and bone erosion accompanying arthritis induced by PG-APS).Histological sections of decalcified ankle joints were prepared from rats sacrificed 4 to 11 days after reactivation. The severity of changes in the synovium, tendons, cartilage, and bone was scored blindly from coded slides. Vehicle were examined microscopically, 51 of 70 joints (73%) also had early damage of the articular surfaces, with marginal erosion of cartilage and sometimes adjacent bone (Fig. 6) .
The joints of rats treated with IL-lra had the same morphological changes as did control joints, but the severity of synovitis and the incidence of erosion were lower ( Fig. 6A  and B) . The reduction in the severity of cartilage and bone erosion depended on the intensity of the suppression of IL-1 activity. As noted above, although less intense schedules of IL-lra treatment could reduce joint swelling, they did not convincingly affect the less sensitive and precise histological assessment. Thus, in comparison with an untreated positive control group, the average score for the severity of synovitis was reduced 63% in a group injected with IL-lra (2 mg/kg) 5 min before and 2 and 6 h after reactivation and then every 6 h for 4 days. The incidences of cartilage erosion were three of nine in the treated group and seven of nine in the control group. In another experiment with a comparable schedule of IL-lra, the incidence of erosion was reduced from 8 of 11 to 4 of 11 and the average score for the severity of synovitis was reduced 59%. In these experiments, joint swelling was also reduced 50 to 60%. However, with a smaller dosage (2 mg/kg at 4 and 10 h after reactivation and then every 12 h for 80 h), the reduction in the severity of synovitis was only 30% and the incidences of erosion were the same in both the control and treated groups. With even less frequent treatment (8.0 mg of IL-lra per kg 5 min before reactivation and then every 12 h for 84 h), the reduction in histological severity was only 11% and the incidences of ankle joints with marginal erosion were five of eight in the treated group and six of eight in the control group, despite the fact that joint swelling was significantly suppressed. (11) , by the measurement of IL-1 in joint effusions (29) , and by the observation that inflammatory cell accumulation and cartilage degradation can be induced by i.a. injection of IL-1 in rabbits (18) , mice (27) , and rats (22) It is not clear which, if any, of the many activities of IL-1 in vivo are responsible for the proposed anti-inflammatory effect. The fact that IL-1 is effective 24 h prior to the induction of recurrence suggests that suppression is a consequence of a cascade triggered by IL-1. Ulich et al. (25) have reported that IL-6 can inhibit tumor necrosis factor and IL-1 expression and have proposed that IL-6 may be part of a negative feedback mechanism. Cominelli et al. (8) have ascribed suppression induced by IL-1 in the colitis model to prostaglandin production, since suppression correlated with colonic prostaglandin E2 production and was reversed by ibuprofen.
The model of reactivation of arthritis in a previously injured joint by i.v. injection of a relatively small dose of PG-APS is a self-limiting disease, possibly because there is no reservoir of PG-APS in the liver or spleen (13, 19) . This self-limiting arthritis is in contrast to the progressive, destructive arthritis characteristic of our earlier model of streptococcal cell wall-induced arthritis produced by a single intraperitoneal (i.p.) injection of PG-APS (9, 19) . However, the PG-APS reactivation model has the features of a chronic inflammatory process, since the histopathology reveals extensive infiltration of the synovium with mononuclear cells and since reactivation requires T lymphocytes and can be suppressed by cyclosporin A (24a). The distinct advantage of the reactivation model is that it provides predictable synchronized recurrences, allowing more precise analysis of the regulation of recurrences. In addition, because it is of a shorter duration (1 to 2 weeks versus several months), the relatively brief administration of a specific inhibitor can yield significant results.
IL-lra provides a unique tool for dissecting the functions of IL-1 in vivo. IL-lra is probably part of a physiological system for regulating normal and pathological activities of IL-1 and other cytokines, since it is an endogenous inhibitor of IL-1, is made by the same cells which secrete IL-1 (15) , and appears to be the same molecule as that found in the urine of human febrile patients and patients with myelomonocytic leukemia (21) .
